The Italian Competition Authority has initiated an investigation against Samsung Bioepis, Biogen, Genentech, and Novartis entities for suspected anticompetitive behavior in the market for ranibizumab, a crucial ingredient in treating eye diseases.

The AGCM alleges that these companies may have coordinated to hinder the entry of a biosimilar drug, Byooviz, developed by Samsung Bioepis and Biogen, which competes with Lucentis, a product of Genentech marketed by Novartis in Italy.

If proven, these actions could distort competition and limit market competition, impacting potential cost savings for the National Health Service and affecting patients and taxpayers by reducing supply options and prices in the pharmaceutical sector.

Inspections were conducted in Italy and the Netherlands, with Italian officials raiding the premises of Biogen Italia, Novartis Farma, and other relevant companies, while the Dutch Competition Authority carried out parallel inspections at Samsung Bioepis NL B.V.